• 1
    Burkhardt H, Bojarsky G, Gretz N, Gladisch R. Creatinine clearance, Cockcroft-Gault formula and cystatin C: estimators of true glomerular filtration rate in the elderly? Gerontology 2002; 48: 140146.
  • 2
    Urakami Y, Kimura N, Okuda M, Inui K. Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res 2004; 21: 976981.
  • 3
    Urakami Y, Kimura N, Okuda M, Masuda S, Katsura T, Inui K. Transcellular transport of creatinine in renal tubular epithelial cell line LLC-PK1. Drug Metab Pharmacokinet 2005; 20: 200205.
  • 4
    Min S, Song I, Borland J, Chen S, Lou Y, Fukiwara T, Piscitelli SC. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2010; 54: 254258.
  • 5
    Van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, Rockstroh JK, Almond S, Song I, Brothers C, Min S. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomized, phase 2b trial. Lancet Infect Dis 2011; 12: 111118.
  • 6
    Min S, Carrod A, Curtis L, Stainsby C, Brothers C, Yeo J, Nichols G. Safety profile of dolutegravir (DTG, S/GSK1349572), in combination with other antiretrovirals in antiretroviral (ART)-naive and ART-experienced adults from two phase IIb studies. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 17–20, 2011. Rome, Italy. Abstract TUPE238. Available at (last accessed 24 April 2012).
  • 7
    Andreev E, Koopman M, Arisz L. A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J Intern Med 1999; 246: 247252.
  • 8
    Burgess E, Blair A, Krichman K, Cutler RE. Inhibition of renal creatinine secretion by cimetidine in humans. Ren Physiol 1982; 5: 2730.
  • 9
    Koteff J, Borland J, Chen S, Song I, Peppercorn A, Koshiba T, Cannon C, Muster H, Piscitelli S. An open label, placebo-controlled study to evaluate the effect of dolutegravir (DTG, S/GSK1349572) on iohexol and para-aminohippurate clearance in healthy subjects. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 17-20, 2011. Chicago, IL. Abstract A1-1728. Available at (last accessed 24 April 2012).
  • 10
    Ginsberg AM, Laurenz MW, Rouse DJ, Whitney KD, Spigelman MK. Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects. Antimicrob Agents Chemother 2009; 53: 37263733.
  • 11
    Gaspari F, Perico N, Ruggenenti P, Mosconi L, Amuchastegui CS, Guerini E, Daina E, Remuzzi G. Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol 1995; 6: 257263.
  • 12
    Brown SC, O'Reilly PH. Iohexol clearance for the determination of glomerular filtration rate in clinical practice: evidence for a new gold standard. J Urol 1991; 146: 675679.
  • 13
    Carroll MF, Temte JL. Proteinuria in adults: a diagnostic approach. Am Fam Physician 2000; 62: 13331340.
  • 14
    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: (2 Suppl. 1): S1266.